Literature DB >> 22130313

Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.

Tadasuke Chitose1, Seiji Hokimoto, Shuichi Oshima, Koichi Nakao, Kazuteru Fujimoto, Yuji Miyao, Hideki Shimomura, Ryusuke Tsunoda, Hideki Maruyama, Toyoki Hirose, Koichiro Yamamoto, Michio Mizobe, Koichi Kaikita, Sunao Nakamura, Hisao Ogawa.   

Abstract

BACKGROUND: The aim of this study was to examine the effect of proton-pump inhibitor (PPI) on clinical outcomes in Japanese patients who undergo coronary stent implantation. METHODS AND
RESULTS: A total of 1,270 patients (males 915, 69 years) were enrolled and dual antiplatelet therapy of aspirin and a thienopyridine derivative was prescribed (clopidogrel 630, ticlopidine 640). Patients were divided into 2 groups treated with or without PPI. PPI was administered in 331 cases (26%), and non-PPI in 939 (74%). There were no significant differences in cardiovascular death (PPI vs. non-PPI: 5 vs. 11 cases), nonfatal myocardial infarction (3 vs. 5), and stroke (3 vs. 16) between PPI and non-PPI groups, but the ratio of gastrointestinal events had a higher tendency in non-PPI group compared with PPI group (1 vs. 17, P=0.08). In subgroup analysis of patients taking clopidogrel, or patients with acute coronary syndrome, there was no significant difference in the ratio of cardiovascular events (7 vs. 16, 6 vs. 17, NS). The non-PPI group had a tendency of an increased risk of gastrointestinal events compared with the PPI group (0 vs. 9, P=0.06; 1 vs. 7, P=0.14).
CONCLUSIONS: In contrast to the negative drug interaction of PPI reported elsewhere, in the present study the intake of PPI was not associated with an increased risk for adverse clinical outcomes in patients treated with stents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22130313     DOI: 10.1253/circj.cj-11-0699

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  11 in total

Review 1.  Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review.

Authors:  Chiara Melloni; Jeffrey B Washam; W Schuyler Jones; Sharif A Halim; Victor Hasselblad; Stephanie B Mayer; Brooke L Heidenfelder; Rowena J Dolor
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-01-13

Review 2.  Clinical roles of calcium channel blockers in ischemic heart diseases.

Authors:  Daisuke Sueta; Noriaki Tabata; Seiji Hokimoto
Journal:  Hypertens Res       Date:  2017-01-26       Impact factor: 3.872

3.  Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.

Authors:  Charles E Leonard; Warren B Bilker; Colleen M Brensinger; David A Flockhart; Cristin P Freeman; Scott E Kasner; Stephen E Kimmel; Sean Hennessy
Journal:  Stroke       Date:  2015-02-05       Impact factor: 7.914

Review 4.  Proton pump inhibitors and potential interactions with clopidogrel: an update.

Authors:  Lauren B Gerson
Journal:  Curr Gastroenterol Rep       Date:  2013-06

Review 5.  Proton pump inhibitors and clopidogrel: an association to avoid?

Authors:  Emilia D'Ugo; Serena Rossi; Raffaele De Caterina
Journal:  Intern Emerg Med       Date:  2013-09-13       Impact factor: 3.397

6.  Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis.

Authors:  Rhanderson N Cardoso; Alexandre M Benjo; James J DiNicolantonio; Daniel C Garcia; Francisco Y B Macedo; Georges El-Hayek; Girish N Nadkarni; Sebastiano Gili; Mario Iannaccone; Ioannis Konstantinidis; John P Reilly
Journal:  Open Heart       Date:  2015-06-30

Review 7.  Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).

Authors:  Pravesh Kumar Bundhun; Abhishek Rishikesh Teeluck; Akash Bhurtu; Wei-Qiang Huang
Journal:  BMC Cardiovasc Disord       Date:  2017-01-05       Impact factor: 2.298

8.  PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis.

Authors:  Alexandra Demcsák; Tamás Lantos; Emese Réka Bálint; Petra Hartmann; Áron Vincze; Judit Bajor; László Czopf; Hussain Alizadeh; Zoltán Gyöngyi; Katalin Márta; Alexandra Mikó; Zsolt Szakács; Dániel Pécsi; Péter Hegyi; Imre László Szabó
Journal:  Front Physiol       Date:  2018-11-19       Impact factor: 4.566

9.  Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.

Authors:  Takashi Kawai; Kazunori Oda; Nobuo Funao; Akira Nishimura; Yasushi Matsumoto; Yuji Mizokami; Kiyoshi Ashida; Kentaro Sugano
Journal:  Gut       Date:  2017-12-01       Impact factor: 23.059

10.  Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018.

Authors:  Joseph Jy Sung; Philip Wy Chiu; Francis K L Chan; James Yw Lau; Khean-Lee Goh; Lawrence Hy Ho; Hwoon-Young Jung; Jose D Sollano; Takuji Gotoda; Nageshwar Reddy; Rajvinder Singh; Kentaro Sugano; Kai-Chun Wu; Chun-Yin Wu; David J Bjorkman; Dennis M Jensen; Ernst J Kuipers; Angel Lanas
Journal:  Gut       Date:  2018-04-24       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.